China
Africa
Explore chapters and articles related to this topic
Osteoarthritis (Knee and Hip)
Published in Charles Theisler, Adjuvant Medical Care, 2023
Glucosamine: Most research shows that taking glucosamine sulfate can provide pain relief for individuals with osteoarthritis, especially those with osteoarthritis of the knees.8 Data from double-blind studies showed glucosamine was superior to ibuprofen in patients with osteoarthritis of the knee.9
Herbal and Supplement Use in Pain Management
Published in Sahar Swidan, Matthew Bennett, Advanced Therapeutics in Pain Medicine, 2020
Drug interactions: Acetaminophen: adding glucosamine to acetaminophen may decrease pain in patients with osteoarthritis. Some research suggests that the sulfate portion of glucosamine sulfate might contribute to its effect in osteoarthritis.79Anti-diabetic drugs: glucosamine might increase insulin resistance or decrease insulin production leading to worsened diabetes and a decrease in effectiveness of diabetic drugs.80Topoisomerase II inhibitors: glucosamine might induce resistance to etoposide and doxorubicin by reducing the drug’s inhibition of topoisomerase II. Other drugs such as mitoxantrone and anthracyclines may also be affected.81Warfarin: taking chondroitin in combination with glucosamine might increase the anticoagulant effects of warfarin and increase risk of bruising and bleeding. May increase INR.76
Glycosaminoglycans
Published in Luke R. Bucci, Nutrition Applied to Injury Rehabilitation and Sports Medicine, 2020
20 m, and walking speed for 20 m. After 21 d, differences between glucosamine and placebo groups were highly significant. The overall symptom score for the glucosamine group was reduced by 80% (7.5 to 1.5), while the placebo group showed a return to pretreatment scores (6.8 to 5.8). Four glucosamine treated patients (27%) became symptom free after 21 d. Although most patients were “severely ill,” no side effects in either group were observed. Thus, a randomized, double-blind, placebo-controlled study found large and significant therapeutic benefits from both injectable and oral glucosamine sulfate for osteoarthritis patients. The short course of study makes the results even more remarkable, considering the chronic nature of osteoarthritis.
Glucosamine for the Treatment of Osteoarthritis: The Time Has Come for Higher-Dose Trials
Published in Journal of Dietary Supplements, 2019
Mark F. McCarty, James H. O'Keefe, James J. DiNicolantonio
Despite the perplexingly inconsistent results of clinical trials evaluating the impact of supplemental glucosamine on pain and joint destruction in osteoarthritis (as well reviewed recently: Henrotin et al., 2012; Wu et al., 2013; Rovati et al., 2012), a large and growing animal literature indicates that, with dosage schedules that typically achieve maximal plasma levels at least several-fold higher than those achieved in clinical trials to date, glucosamine can exert a range of intriguing anti-inflammatory and cytoprotective effects. The utility of glucosamine in adjuvant-induced arthritis in rats is especially well documented (Hua et al., 2005; Gilzad-Kohan & Jamali, 2012; Gilzad-Kohan et al., 2013; Aghazadeh-Habashi et al., 2014), but this agent has also been reported useful in other arthritis models, such as those in which arthritis is induced with collagen injection or mechanical damage (anterior cruciate ligament transection; Haleagrahara et al., 2013; Wang et al., 2007). Most recently, oral glucosamine was reported to ameliorate the course of spontaneous osteoarthritis in Hartley guinea pigs and STR/ort mice (Taniguchi et al., 2012; Chiusaroli et al., 2011). As long ago as 1991, Setnikar et al. (1991) reviewed the already ample literature demonstrating that glucosamine sulfate had a beneficial impact on four different models of arthritis in rodents, in oral doses ranging from 50 to 800 mg/kg daily.
Non-surgical treatment before hip and knee arthroplasty remains underutilized with low satisfaction regarding performance of work, sports, and leisure activities
Published in Acta Orthopaedica, 2020
Yvonne Van Zaanen, Alexander Hoorntje, Koen L M Koenraadt, Leti Van Bodegom-Vos, Gino M M J Kerkhoffs, Suzanne Waterval-Witjes, Tim A E J Boymans, Rutger C I Van Geenen, P Paul F M Kuijer
Of the SCS treatments of step 1, acetaminophen was received most often (hip 73%, knee 79%; p = 0.4) and lifestyle advice least often (hip 60%, knee 62%; p = 0.9) (Figure 2). Glucosamine sulfate was received by 18% of hip OA patients and 21% of knee OA patients (p = 0.7). Of the SCS treatments of step 2, exercise-based therapy was received most often by patients (hip 66%, knee 59%; p = 0.4), while diet therapy among overweight patients (hip 23%, knee 19%; p = 0.3) and tramadol (hip 11%, knee 20%; p = 0.1) were least often received. Intra-articular injections, the SCS step 3 treatment, were more often received by knee OA patients (47%) than by hip OA patients (10%; p < 0.01).